CN111345470B - 中药组合物在制备具有降脂功效的药品中的应用 - Google Patents
中药组合物在制备具有降脂功效的药品中的应用 Download PDFInfo
- Publication number
- CN111345470B CN111345470B CN201811582923.7A CN201811582923A CN111345470B CN 111345470 B CN111345470 B CN 111345470B CN 201811582923 A CN201811582923 A CN 201811582923A CN 111345470 B CN111345470 B CN 111345470B
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- medicine composition
- lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 51
- 239000000203 mixture Substances 0.000 title claims abstract description 50
- 230000000694 effects Effects 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 229940079593 drug Drugs 0.000 title description 6
- 239000002994 raw material Substances 0.000 claims abstract description 16
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 12
- 235000007516 Chrysanthemum Nutrition 0.000 claims abstract description 12
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 12
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 12
- 244000235756 Microcos paniculata Species 0.000 claims abstract description 12
- 244000215777 Plumeria rubra Species 0.000 claims abstract description 12
- 235000013087 Plumeria rubra Nutrition 0.000 claims abstract description 12
- 244000179560 Prunella vulgaris Species 0.000 claims abstract description 12
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 12
- 235000011477 liquorice Nutrition 0.000 claims abstract description 12
- 235000008113 selfheal Nutrition 0.000 claims abstract description 12
- 241001646828 Platostoma chinense Species 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 241000723353 Chrysanthemum Species 0.000 claims description 11
- 238000000605 extraction Methods 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims 1
- 238000007654 immersion Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 235000013305 food Nutrition 0.000 abstract description 15
- 241000244203 Caenorhabditis elegans Species 0.000 abstract description 5
- 230000008021 deposition Effects 0.000 abstract description 5
- 238000011160 research Methods 0.000 abstract description 2
- 244000189548 Chrysanthemum x morifolium Species 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 241000244206 Nematoda Species 0.000 description 28
- 239000000523 sample Substances 0.000 description 14
- 239000000047 product Substances 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000036541 health Effects 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 235000015092 herbal tea Nutrition 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- QJYNZEYHSMRWBK-NIKIMHBISA-N 1,2,3,4,6-pentakis-O-galloyl-beta-D-glucose Chemical compound OC1=C(O)C(O)=CC(C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(O)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(O)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(O)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(O)C(O)=C(O)C=2)=C1 QJYNZEYHSMRWBK-NIKIMHBISA-N 0.000 description 2
- 241001167795 Escherichia coli OP50 Species 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000008057 potassium phosphate buffer Substances 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 1
- 101100149536 Caenorhabditis elegans skn-1 gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 239000012880 LB liquid culture medium Substances 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 101100083855 Rattus norvegicus Pou2f3 gene Proteins 0.000 description 1
- 102100026715 Serine/threonine-protein kinase STK11 Human genes 0.000 description 1
- 101710181599 Serine/threonine-protein kinase STK11 Proteins 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000010196 hermaphroditism Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- JTSLALYXYSRPGW-UHFFFAOYSA-N n-[5-(4-cyanophenyl)-1h-pyrrolo[2,3-b]pyridin-3-yl]pyridine-3-carboxamide Chemical compound C=1C=CN=CC=1C(=O)NC(C1=C2)=CNC1=NC=C2C1=CC=C(C#N)C=C1 JTSLALYXYSRPGW-UHFFFAOYSA-N 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- BAZAXWOYCMUHIX-UHFFFAOYSA-M sodium perchlorate Chemical compound [Na+].[O-]Cl(=O)(=O)=O BAZAXWOYCMUHIX-UHFFFAOYSA-M 0.000 description 1
- 229910001488 sodium perchlorate Inorganic materials 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/34—Tea substitutes, e.g. matè; Extracts or infusions thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/536—Prunella or Brunella (selfheal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Food Science & Technology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明涉及一种中药组合物在制备具有降脂功效的食品、药品或保健品中的应用,所述中药组合物,由包括如下重量份的原料组分制成:仙草1000~3500份、鸡蛋花135~900份、布渣叶45~900份、菊花180~900份、金银花180~900份、夏枯草180~900份、甘草45~900份。通过研究发现:该中药组合物能够显著降低秀丽线虫的体内脂肪沉积,具有良好的降脂的作用,能够用于制备具有降脂功效的食品,提供了该中药组合物的新用途,也为降脂提供了新的途径。
Description
技术领域
本发明涉及中药组合物的新应用,特别是涉及一种中药组合物在制备具有降脂功效的药品中的应用。
背景技术
从现代医学的角度来说,肥胖至少有以下几个“祸点”。第一,造成体态笨重,活动不便,心理障碍;第二,衣食住行花费增加。另外肥胖最大的危害是可导致一系列严重的并发症,比如高血压病、糖尿病、血脂紊乱、冠心病、恶性肿瘤等,这些疾病都是人类健康的主要杀手。
传统的减肥方式是加强运动或节食,但是现代人生活节奏较快,较难有时间进行特定的减肥运动,至于节食则较难长期坚持。
中国专利CN102793038A公开一种中药组合物,其原料组成包括仙草 1000~3500份、鸡蛋花135~900份、布渣叶45~900份、菊花180~900份、金银花180~900份、夏枯草180~900份、甘草45~900份。各原料组分互相配伍,具有祛火除湿、清热解毒、生津止渴的功效。
发明内容
基于此,有必要提供一种中药组合物在制备具有降脂功效的食品、药品或保健品中的应用。
一种中药组合物在制备具有降脂功效的食品、药品或保健品中的应用,所述中药组合物,由包括如下重量份的原料组分制成:
仙草1000~3500份、鸡蛋花135~900份、布渣叶45~900份、菊花180~900 份、金银花180~900份、夏枯草180~900份、甘草45~900份。
在其中一个实施例中,所述中药组合物,由包括如下重量份的原料组分制成:
仙草1500~2500份、鸡蛋花300~500份、布渣叶300~500份、菊花300~500 份、金银花300~500份、夏枯草300~500份、甘草300~500份。
在其中一个实施例中,所述中药组合物,由包括如下重量份的原料组分制成:
仙草1900~2500份、鸡蛋花350~450份、布渣叶350~450份、菊花350~450 份、金银花350~450份、夏枯草350~450份、甘草350~450份。
在其中一个实施例中,所述中药组合物的制备方法包括如下步骤:
按照配方量配制各原料组分后,加水提取;
浓缩所得提取液,得浓缩液,即可。
在其中一个实施例中,所述水的用量为所述原料组分重量的6-20倍。
在其中一个实施例中,所述提取的时间为0.5-3h。
在其中一个实施例中,加水后,先浸泡10-50分钟,再进行所述提取。
在其中一个实施例中,所述浓缩液的浓度为9-14Be。
在其中一个实施例中,所述中药组合物还包括食品、药品、保健品上可接受的辅料。
在其中一个实施例中,所述食品为凉茶。
与现有技术相比,本发明具有如下有益效果:
本发明提供了活性成分主要为仙草、鸡蛋花、布渣叶、菊花、金银花、夏枯草、甘草的中药组合物的新应用。通过研究发现:该中药组合物能够显著降低秀丽线虫的体内的脂肪沉积,具有良好的降脂的作用,能够用于制备具有降脂、减肥功效的药品、保健品或食品,提供了该中药组合物的新用途,也为降脂、减肥提供了新的途径。另外,该中药组合物可以作为饮料饮用,在日常饮食中即可达到降脂减肥的目的,符合现代人的需求。
附图说明
图1为经染色处理后空白组和实验组的虫体染色情况;
图2为空白组和实验组的虫体内脂肪的含量(染色的强度)情况。
具体实施方式
以下结合具体实施例对本发明的中药组合物在制备具有降脂功效的药品、保健品或食品中的应用作进一步详细的说明。
实施例1
本实施例为所述中药组合物在制备具有降脂功效的药品、保健品或食品中的应用研究。
1、材料与方法
1.1实验试剂及设备
1.1.1实验试剂
线虫生长固体培养基(NGM)配制:NaCl,蛋白胨,琼脂,链霉素,胆固醇,CaCl2,MgSO4,制霉菌素。线虫裂解液配制:NaOH,家用漂白剂。N2野生型秀丽隐杆线虫(C.elegans,the Bristol strain N2),雌雄同体。大肠杆菌OP50 (Escherchia coli OP50;E.coliOP50):尿嘧啶合成缺陷菌株,在NGM上生长缓慢,不影响在显微镜下观察线虫的清晰度。
中药组合物试样:由如下重量份的原料组分制成:仙草2200份、鸡蛋花400 份、布渣叶400份、菊花400份、金银花400份、夏枯草400份、甘草400份。制备方法如下:
1)原料处理:选择用于制备中药组合物试样的中药原材料,洗净、切碎之后按照配方量配制;
2)水提:于所述原材料中加入6倍于原材料重量的水,浸泡15分钟后,提取1h,得水提液;
3)浓缩:将所述水提液浓缩至浓度为9Be,得中药组合物试样。该中药组合物试样经过灭菌包装后即为凉茶。也可进一步加入药品、保健品、食品上可接受的辅料制成药品、保健品或凉茶之外的其它食品。
1.1.2设备
表2.1实验主要仪器
2.2实验溶液及培养基的配制
①1M磷酸钾缓冲液:KH2PO4 108.39g,K2HPO4 35.69g,加水至1L,调pH 值至6.0。
②M9缓冲液:KH2PO4 3g,Na2HPO4 6g,NaCl 5g,MgSO4 0.12g,加入蒸馏水至1L,121℃高压灭菌20min。
③线虫裂解液:NaOH 0.1g,加4mL纯水和1mL NaCl,混合摇匀。线虫裂解液现配现用。
④LB液体培养基:LB肉汤21g,加水至1L,121℃灭菌15分钟,宜现用现配。
⑤线虫生长固体培养基(Nematode Growth Medium,NGM):氯化钠3g,琼脂粉17g,胰蛋白胨2.5g,加入975mL蒸馏水,121℃,高压灭菌30min,然后在无菌条件下加入5mg/mL胆固醇1ml(用无水乙醇配制),1M CaCl2、1M MgSO4各1mL和1M pH6.0磷酸钾缓冲液25mL。摇匀后,在无菌条件下,将培养基分装到培养皿(直径55mm平板)中,10mL/板,用前在室温下放置2至3天,再涂布菌液。
2.3实验方法
2.3.1线虫的准备
①线虫的培养与传代
参照文献方法(S.Brenner,The genetics of caenorhabditis elegans,Genetics77:71-94,May 1974),在无菌条件下,切一块含有线虫较多的培养基,转移新的OP50的NGM培养基上即可,在标准培养条件(20℃,湿度40~60%) 下培养,线虫会自动由食物较少的培养基边缘爬到食物较多菌苔中去。由于线虫非常容易通过培养基表面空隙钻入琼脂内,因此培养线虫时,应尽量选择表面光滑,无气泡、划痕的琼脂板。约培养48小时,可进行同期化。
②线虫的同期化
高氯酸钠漂白法(Brian Onken et al.,Metformin induces a dietaryrestriction-like state and the oxidative stress response to extend C.eleganshealthspan via AMPK,LKB1,and SKN-1,PLOS one:January 2010,Volume5,Issue1,8758):在无菌条件下,用已高温灭菌的M9缓冲溶液将正处于产卵期的线虫洗至2mL无菌管中,加1mL裂解液裂解线虫,振荡3~5min,置低速离心机上3000rpm离心 1min,弃上清,再用M9冲洗线虫2次,置低速离心机上3000rpm离心1min,弃上清后用移液枪吸取2mL无菌管底部剩余的0.1mL线虫滴于NGM的无菌区,在标准培养条件下培养,约51h后裂解的线虫体内的受精卵基本发育成L4期幼虫,完成同期化用于试验。
2.3.2不含与含所述中药组合物试样的NGM的配制
①E.coli OP50的培养
挑取OP50的菌种接于100mL LB液体培养基中,在37℃,170rpm条件下,振荡培养12h,至OD600=0.4,用于接种NGM喂养正常组线虫。培养好的菌液不是立即使用完,用10mL无菌管分装约每管8mL置于4℃医用冷藏箱中备用。
②不含所述中药组合物试样NGM的配制
在每个NGM平板上加适量的OP50菌液(一般直径55mm平板加100μL),用移液器取100μL OP50菌液均匀地涂布在NGM平板中央,尽量使菌液边缘距离平板边缘0.5cm左右。涂布好细菌的NGM平板在室温(21~25℃)下过夜后即可使用,若不是立即使用则将其封膜倒置置于4℃医用冷藏箱中备用。
③含所述中药组合物试样NGM的配制
根据浓度10mg/mL,在无菌环境下用10mL容量瓶分别称取100mg所述中药组合物试样,用OP50菌液定容至10mL。涂布方法同不含所述中药组合物试样NGM的配制。置于4℃冷藏箱内的平板2周内尽快用完。
2.3.4所述中药组合物试样对线虫体内脂肪沉积的影响
参照文献方法(Yunjiao Chen,Brian Onken,et al.,Mechanism of longevityextension of caenorhabditis elegans induced by pentagalloyl glucose isolatedfrom eucalyptus leaves,J Agric.Food Chem.2014,62,3422-3431),将刚裂解好的卵加入各组平板上,并放入20℃恒温生化培养箱中培养至L4期幼虫。挑取同步化的 L4期幼虫到新的各组平板上(每组3个平板,每个平板30条)继续培养。线虫生殖期每天将线虫转移到新的各组平板中,其它时期每两天转移到新的平板中,以保证处理化合物的浓度。将第7天(线虫存活天数从卵孵化第一天算起)的线虫用油红O染液染色,每组随机选择15条线虫放置在载玻片上,进行放大 100倍拍照,用单色数码相机以及image J软件分析对比染色强度。每组至少重复3次。
空白组(不含所述中药组合物试样NGM,Control组):油红O染液配制→大肠杆菌(E.coil)的培养,添加一定量的蒸馏水进行对照→虫体的培养→虫体的染色观察。
实验组(含所述中药组合物试样NGM):油红O染液配制→大肠杆菌(E.coil) 的培养,并添加相同量样品溶液(相应浓度的所述中药组合物试样)→虫体的培养→虫体的染色观察。
2.4所述中药组合物试样对线虫体内脂肪沉积的影响检测结果
在显微镜下观察,经染色处理后,虫体有不同程度的着色现象,染色强度与体内脂肪相对含量呈正比。与空白组相比,在实验组的培养基上生长的虫体内染色均比空白组培养基上的虫体颜色浅(图1),经定性分析染色强度结果如图2(其中,a、b代表实验组与Control组之间差异的显著性,a代表Control 组,实验组为a代表无差异,为b代表差异显著)。与空白组相比,含所述中药组合物试样处理7天后即能显著降低线虫体内的脂肪含量。
综上可知,所述的活性成分为仙草、鸡蛋花、布渣叶、菊花、金银花、夏枯草和甘草的中药组合物能够显著减少线虫体内脂肪沉积,具有良好的降脂的作用,能够应用于制备具有降脂功效的食品、药品或保健品。
以上所述实施例的各技术特征可以进行任意的组合,为使描述简洁,未对上述实施例中的各个技术特征所有可能的组合都进行描述,然而,只要这些技术特征的组合不存在矛盾,都应当认为是本说明书记载的范围。
以上所述实施例仅表达了本发明的几种实施方式,其描述较为具体和详细,但并不能因此而理解为对发明专利范围的限制。应当指出的是,对于本领域的普通技术人员来说,在不脱离本发明构思的前提下,还可以做出若干变形和改进,这些都属于本发明的保护范围。因此,本发明专利的保护范围应以所附权利要求为准。
Claims (10)
1.一种中药组合物在制备具有降脂功效的药品中的应用,所述中药组合物,由如下重量份的原料组分制成:
仙草1000~3500份、鸡蛋花135~900份、布渣叶45~900份、菊花180~900份、金银花180~900份、夏枯草180~900份、甘草45~900份。
2.根据权利要求1所述的应用,其特征在于,所述中药组合物,由如下重量份的原料组分制成:
仙草1500~2500份、鸡蛋花300~500份、布渣叶300~500份、菊花300~500份、金银花300~500份、夏枯草300~500份、甘草300~500份。
3.根据权利要求2所述的应用,其特征在于,所述中药组合物,由如下重量份的原料组分制成:
仙草1900~2500份、鸡蛋花350~450份、布渣叶350~450份、菊花350~450份、金银花350~450份、夏枯草350~450份、甘草350~450份。
4.根据权利要求3所述的应用,其特征在于,所述中药组合物,由如下重量份的原料组分制成:
仙草2200份、鸡蛋花400份、布渣叶400份、菊花400份、金银花400份、夏枯草400份、甘草400份。
5.根据权利要求1所述的应用,其特征在于,所述中药组合物的制备方法包括如下步骤:
按照配方量配制各原料组分后,加水提取;
浓缩所得提取液,得浓缩液,即可。
6.根据权利要求5所述的应用,其特征在于,所述水的用量为所述原料组分重量的6-20倍。
7.根据权利要求5所述的应用,其特征在于,所述提取的时间为0.5-3h。
8.根据权利要求5所述的应用,其特征在于,加水后,先浸泡10-50分钟,再进行所述提取。
9.根据权利要求5所述的应用,其特征在于,所述浓缩液的浓度为9-14Be。
10.根据权利要求1-9任一项所述的应用,其特征在于,所述中药组合物还包括药品上可接受的辅料。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811582923.7A CN111345470B (zh) | 2018-12-24 | 2018-12-24 | 中药组合物在制备具有降脂功效的药品中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811582923.7A CN111345470B (zh) | 2018-12-24 | 2018-12-24 | 中药组合物在制备具有降脂功效的药品中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111345470A CN111345470A (zh) | 2020-06-30 |
CN111345470B true CN111345470B (zh) | 2022-07-19 |
Family
ID=71188469
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811582923.7A Active CN111345470B (zh) | 2018-12-24 | 2018-12-24 | 中药组合物在制备具有降脂功效的药品中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111345470B (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1857097A (zh) * | 2006-06-06 | 2006-11-08 | 孙健 | 养肝降脂果丹食品及其制造方法 |
CN101675945A (zh) * | 2008-09-17 | 2010-03-24 | 广东杏林春凉茶有限公司 | 仙草多酚提取物新用途 |
CN105410909A (zh) * | 2015-11-27 | 2016-03-23 | 黑龙江众生生物工程有限公司 | 一种木芙蓉消脂减肥颗粒及其制备方法 |
CN105432871A (zh) * | 2014-09-29 | 2016-03-30 | 吴同忠 | 用于治疗肥胖症的山楂银菊茶 |
JP2017085986A (ja) * | 2015-11-11 | 2017-05-25 | アサヒ飲料株式会社 | 茶飲料、難消化性デキストリンの紙臭又は糊味の抑制剤、及び難消化性デキストリンの紙臭又は糊味の抑制方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101904384B (zh) * | 2010-08-09 | 2013-03-13 | 云南纳西泉食品饮料有限责任公司 | 一种普洱凉茶饮料及其制备方法 |
CN102793038A (zh) * | 2012-08-01 | 2012-11-28 | 广州王老吉药业股份有限公司 | 一种中草药凉茶浓缩液及其制备方法 |
-
2018
- 2018-12-24 CN CN201811582923.7A patent/CN111345470B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1857097A (zh) * | 2006-06-06 | 2006-11-08 | 孙健 | 养肝降脂果丹食品及其制造方法 |
CN101675945A (zh) * | 2008-09-17 | 2010-03-24 | 广东杏林春凉茶有限公司 | 仙草多酚提取物新用途 |
CN105432871A (zh) * | 2014-09-29 | 2016-03-30 | 吴同忠 | 用于治疗肥胖症的山楂银菊茶 |
JP2017085986A (ja) * | 2015-11-11 | 2017-05-25 | アサヒ飲料株式会社 | 茶飲料、難消化性デキストリンの紙臭又は糊味の抑制剤、及び難消化性デキストリンの紙臭又は糊味の抑制方法 |
CN105410909A (zh) * | 2015-11-27 | 2016-03-23 | 黑龙江众生生物工程有限公司 | 一种木芙蓉消脂减肥颗粒及其制备方法 |
Non-Patent Citations (4)
Title |
---|
Analysis of Pogostemon cablin from pharmaceutical research to market performances;Chen M,et al;《Expert Opin Investig Drugs》;20131231;第22卷(第02期);第245-257页 * |
中国凉粉草资源的研究与利用;谌国莲,等;《农牧产品开发》;20000525;第01卷(第05期);第6-8页 * |
凉粉草质量控制及体外降脂作用初步研究;魏星任;《中国知网-总库》;20171231(第01期);第1-69页 * |
大孔树脂纯化复方四叶减肥汤中总黄酮成分的研究;卫强,等;《中药材》;20111025;第34卷(第10期);第1612-1615页 * |
Also Published As
Publication number | Publication date |
---|---|
CN111345470A (zh) | 2020-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101216251B1 (ko) | 차?발효 음료 및 차 음료 | |
Daniyan et al. | Evaluation of the antimicrobial activities and phytochemical properties of extracts of Tamaridus indica against some diseases causing bacteria | |
KR102250597B1 (ko) | 신규 유산균 및 이의 용도 | |
Siavoshi et al. | Natural fruits, flowers, honey, and honeybees harbor Helicobacter pylori‐positive yeasts | |
JP2018153182A (ja) | ラクトバチルスプランタルムtci378、およびそれを用いた脂肪の減少および胃腸機能の改善における使用 | |
CN103446552B (zh) | 用于预防和治疗消化系统疾病的发酵组合物 | |
Ogundare et al. | The antimicrobial activity of Morinda lucida leaf extract on Escherichia coli | |
CN111904993B (zh) | 中药组合物在制备具有抗衰老功效的药品中的应用 | |
CN108853358B (zh) | 一种抗菌中药组合物及其制备方法和用途 | |
CN111345470B (zh) | 中药组合物在制备具有降脂功效的药品中的应用 | |
CN101322746B (zh) | 二次发酵法天然药物制剂、制备方法及用途 | |
EP1297837A1 (en) | Remedies for allergic diseases and process for producing the same | |
CN102905715A (zh) | 含有香豆雌酚或包含香豆雌酚的豆提取物的组合物 | |
CN115927116B (zh) | 一种具有降甘油三酯、降胆固醇、减脂的发酵乳杆菌菌株及其应用 | |
CN111345471B (zh) | 中药组合物在制备具有减少老年斑功效的药品中的应用 | |
CN111903810A (zh) | 中药组合物在制备具有抗应激功效的食品、药品、保健食品或饲料中的应用 | |
CN111904994B (zh) | 中药组合物在制备防治神经退行性疾病的药品中的应用 | |
CN101914458B (zh) | 白假丝酵母(甘露糖蛋白质复合体)菌毛株 | |
Abbas et al. | Isolation and Screening of Actinomycetes producing Antibacterial compounds from different river sediments | |
KR102007569B1 (ko) | 기호도 및 기능성이 향상된 섬애쑥 발효물 및 이의 제조방법 | |
CN106177035B (zh) | 具有降血糖、抗癌的月季花有效提取物的制备方法及应用 | |
CN108740006A (zh) | 酸枣抗菌增敏活性成分及其制备方法和应用 | |
Mujahid et al. | In-vitro Antifungal Evaluation of Cinnamomum zeylanicum and Leptadenia hastata on Malassezia species | |
Abbas et al. | SCREENING AND ISOLATION OF ACTINOMYCETESS FROM RIVER SEDIMENTS | |
CN106491671A (zh) | 一种鸦胆子油乳、制备方法及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |